TransMedics Group, Inc. (NASDAQ:TMDX) Stake Lifted by Driehaus Capital Management LLC

Driehaus Capital Management LLC grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 15.8% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,486,073 shares of the company’s stock after buying an additional 202,867 shares during the period. TransMedics Group accounts for approximately 2.1% of Driehaus Capital Management LLC’s portfolio, making the stock its 3rd largest position. Driehaus Capital Management LLC’s holdings in TransMedics Group were worth $223,832,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Wasatch Advisors LP purchased a new position in shares of TransMedics Group in the 1st quarter valued at approximately $32,162,000. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of TransMedics Group during the second quarter worth $39,862,000. First Light Asset Management LLC grew its position in TransMedics Group by 22.0% in the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after buying an additional 136,217 shares during the last quarter. Hood River Capital Management LLC acquired a new position in TransMedics Group in the 2nd quarter valued at $18,854,000. Finally, Canada Pension Plan Investment Board acquired a new position in TransMedics Group in the 2nd quarter valued at $16,086,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,948,714.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,267,557.11. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,948,714.31. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock worth $9,650,880 over the last ninety days. 7.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TMDX. TD Cowen lifted their target price on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Canaccord Genuity Group lifted their price objective on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Stephens increased their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Needham & Company LLC assumed coverage on TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price target on the stock. Finally, Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $174.30.

TransMedics Group Stock Up 10.1 %

TMDX opened at $159.14 on Friday. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. The company has a market cap of $5.24 billion, a price-to-earnings ratio of -468.06 and a beta of 1.99. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $177.37. The business’s fifty day moving average is $156.02 and its two-hundred day moving average is $130.87.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. During the same period in the previous year, the firm earned ($0.03) EPS. The business’s revenue for the quarter was up 117.7% compared to the same quarter last year. Analysts anticipate that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.